Ignite Creation Date:
2025-12-24 @ 11:35 PM
Ignite Modification Date:
2025-12-25 @ 9:25 PM
Study NCT ID:
NCT00603356
Status:
COMPLETED
Last Update Posted:
2011-09-27
First Post:
2007-12-26
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Phase I Study of OSI-930 and Erlotinib in Cancer Tumors
Sponsor:
Astellas Pharma Inc
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2007-11
Start Date Type:
None
Primary Completion Date:
2010-04
Primary Completion Date Type:
ACTUAL
Completion Date:
2010-07
Completion Date Type:
ACTUAL
First Submit Date:
2007-12-26
First Submit QC Date:
None
Study First Post Date:
2008-01-29
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2011-09-26
Last Update Post Date:
2011-09-27
Last Update Post Date Type:
ESTIMATED